(Q45227579)

11 December 2017

title

Single-agent thalidomide induces response in T-cell lymphoma (English)

1 reference

11 December 2017

0 references

Damaj G

1

1 reference

11 December 2017

Bouabdallah R

2

1 reference

11 December 2017

Vey N

3

1 reference

11 December 2017

Bilger K

4

1 reference

11 December 2017

Mohty M

5

1 reference

11 December 2017

Gastaut JA

6

1 reference

11 December 2017

publication date

1 February 2005

1 reference

European Journal of Haematology

11 December 2017

published in

1 reference

11 December 2017

volume

74

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

169-171

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Thalidomide therapy induces response in relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Response to thalidomide in multiple myeloma: impact of angiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

Efficacy of a low dose of thalidomide in advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00362.X

10.1111/J.1600-0609.2004.00362.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference